Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2019-08-13
Target enrollment:
Participant gender:
Summary
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent
of patients don't respond to current treatments. MBS2320, the drug being tested in this
trial, represents a new approach to treating RA, with the potential not only to reduce levels
of inflammation but to also directly prevent bone damage.The aim of this project is to test
the safety, tolerability and efficacy of MBS2320 in patients with RA in combination with an
existing treatment, methotrexate.